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Background/aim: Diabetes mellitus is a risk factor for cardiovascular diseases (CVDs), which are among the major causes of deaths in
type 2 diabetes (T2D). The purpose of the present study was to determine the association of C282Y and H63D mutations in the HFE
gene with increased risk of coronary artery disease (CAD) in T2D patients.
Materials and methods: Two hundred and ninety individuals were divided into two groups: a case group and a control group. Genomic
DNA of peripheral venous blood cells was extracted and the HFE gene mutations were analyzed using the PCR–RFLP technique.
Results: Data analysis revealed a significant difference between the allele frequencies of H63D and C282Y mutations between the
case group and the controls (P < 0.05). The relationships between the GA and GG genotypes in C282Y and H63D mutations in terms
of fasting blood sugar (FBS), lipid profile (total cholesterol, triglycerides, high-density lipoproteins (HDL), low-density lipoproteins),
body mass index (BMI), HbA1c, micro albuminuria, and creatine levels did not show a significant differences between the two groups
(P > 0.05). Using a logistic regression model, BMI, FBS, HDL, and total cholesterol levels were significantly different with independent
predictors of CVD (P < 0.05).
Conclusion: Our results revealed a significant correlation between C282Y and H63D mutations and the development of CAD in T2D
patients
Key words: Type 2 diabetes, coronary artery disease, HFE gene, H63D and C282Y mutations

1. Introduction
It is well-established that diabetes mellitus is a risk factor
for cardiovascular end points, which is the major cause of
death in type 2 diabetes (T2D) (1,2). Several studies (3,4)
have reported the association between higher iron storage
and an increased risk of T2D mellitus. Many studies
indicate that there are genes associated with increased risk
of T2D mellitus, such as genes involved in iron metabolism
{DEMİRBİLEK H , 2013 #19}(5,6). HFE gene variants were
observed to be associated with iron overload (7,8). HFE
gene variants cause hereditary hemochromatosis (HH),
which often results in an increased risk of coronary artery
disease (CAD) (9,10). It has been known for a long time
that T2D mellitus accounts for 50% and 80% of patients
* Correspondence: saber.imani@yahoo.com
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with hemochromatosis (9), which causes an increased risk
of CAD (10,11). Iron overload causes iron depots in some
organs including the heart, which have been associated
with CAD and reduced life expectancy (12).
Among the various genetic variants in the HFE gene
region (13,14), 2 missense mutations, including a cysteine
to tyrosine substitution at the amino acid position 282
(C282Y) and a histidine to aspartate substitution at the
amino acid position 63 (H63D), have been the most
investigated (7). The HFE gene product is a human
leukocyte antigen-like molecule that is presented at the cell
surface bound to β2-microglobulin, where it is thought to
modify the affinity of transferrin for its receptor. These
mutations are considered to be independent risk factors
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for diabetic nephropathy (2). Some studies also reported
an increased risk of myocardial infarction (15) and
CAD in C282Y and Cys282Tyr in carriers (12,16). Most
published studies are cross-sectional, with a restricted
number of potentially explanatory variables (13,15). Thus,
considering the relationship between HFE mutations and
the clinical features and complications of diabetes (such
as lipid profile and body mass index (BMI) among others)
is very important (2). In the present study, we aimed to
assess whether or not mutations in the HFE gene might be
associated with increased risk of CAD in type 2 diabetic
patients. To our knowledge this is the first study conducted
on Iranian population in this regard.
2. Materials and methods
This cross sectional case-control study is based on 290
individuals of Iranian ancestry. This population included
patients with angina-like chest pain and noninvasive tests
suggesting ischemia, indicating patients with depressed
left ventricular ejection fraction of unknown origin and
valvular heart disease. Patients with previously performed
coronary bypass surgery or percutaneous transluminal
coronary angioplasty were excluded from the analysis
because of their treated coronary status. Participants who
had a fasting blood glucose concentration >6.7 mmol/L, a
blood glucose concentration of >10.0 mmol/L 2 h after a
glucose load, and clinical diagnosis of diabetes requiring

dietary, oral, or insulin treatment were considered as
T2D. Patients with thyroid, liver, or renal diseases were
excluded from the study. The patient group included 145
CAD patients with positive coronary angiograms (at least
one vessel with >50% stenosis) with a history of T2D who
attended the Shahid Chamran Hospital (Tehran University
of Medical Sciences, Tehran, Iran).
The control group (with no evidence of CAD (no
history of angina and normal resting ECG (17)) consisted
of 145 individuals recruited from the general population
in the same geographical region. All participants were
matched for age and sex, with the number of women
and men being similar in both groups. All participants
gave written informed consent to the use of their blood
for genetic analysis, and this study conformed to the
principles of the Declaration of Helsinki. The local hospital
ethics committee approved this study. At the time of blood
sampling, patients were under their usual cardiovascular
medications. Characteristics of the study population,
including sex and age, in both groups are shown in Table 1.
After inclusion, clinical and laboratory data were
collected for each patient from the clinical charts. The
following variables were considered and analyzed in the
present study: serum glucose, total cholesterol, highdensity lipoproteins (HDL), low-density lipoproteins
(LDL), triglycerides (TG), BMI, HbA1c, creatine (Cr), and
microalbumin.

Table 1. Characteristics of the study population.
Characteristics

CAD subjects

Control subjects

P value

N (m/f)

72/73

71/74

0.831

Mean age (years)

53.9 ±9

51.3 ± 10

0.423

Mean weight (kg)

89.2 ± 3.8

86.3 ± 4.4

0.577

Systolic BP (mmHg)

139.5 ± 24.8

131.2 ± 19.8

0.001

Diastolic BP (mmHg)

80.2 ±11.8

83.6 ±9.4

0.002

Total cholesterol (mg/dL)

204.1 ±28.4

198.8 ± 34.1

0.001

BMI (kg/m2)

29.4 ± 4.5

24.6 ± 2.6

0.756

FBS (mg/dL)

182.1 ± 20.3

189.6 ± 43.1

0.572

2 h plasma glucose (mmol/L)

9.1 ± 3.1

5.4 ± 7.4

0.012

Cr. (mg/dL)

1.02 ± 0.42

0.96 ± 0.2

0.031

TG (mg/dL)

112 ± 36.09

99 ± 40.4

0.112

HDL-C (mg/dL)

49.0 ± 9.7

45.0 ± 7.3

0.490

LDL-C (mg/dL)

103.0 ± 21.2

98.03 ± 12.5

0.471

HbA1c (%)

8.63 ± 1.2

8.23 ± 7.0

0.810

Microalbumin (mg/dL)

19.03 ± 6.6

11.12 ± 5.6

0.420

All data are expressed as a means (± SD), CAD: coronary artery disease; BMI: body mass
index; FBS: fasting blood sugar, Cr: Creatine; TG: Triglycerides; HDL-C: high-density
lipoprotein–cholesterol; LDL-C: low-density lipoprotein–cholesterol.
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DNA was isolated from venous blood samples using
Bioneer kit (Bioneer). To evaluate the prevalence of mutations
in the HFE gene in the patient and control groups, PCR
amplification and RFLP analysis were performed. PCR was
performed for amplification of the C282Y and H63D sites
using primers designed by Prime3plus software available
on
http://www.bioinformatics.nl/cgi-bin/primer3plus/
primer3plus.cgi. For H63D locus, the forward and reverse
primers were 5’-ATGGTTAAGGCCTGTTGCTCTGTC
and 5’-CCCTTGCTGTGGTTGTGATTTTC, respectively;
for C282Y locus, the forward and reverse designed
primers were 5’-TCCTCTTTCCTGTCAAGTGC and
5’-GATGACTCCAATGACTAGGG, respectively.
DNA was amplified under the following conditions:
initial denaturation at 95 °C for 5 min, followed by 30
cycles of denaturation at 94 °C for 30 s, annealing at 61
°C (for H63D mutation) and 57 °C ( for C282Y mutation)
for 30 s, extension at 72 °C for 30 s, and a final extension
at 72 °C for 5 min. Then PCR amplification was followed
by restriction enzyme cleavage: a 10 µL sample of the PCR
product was digested in 20 µL reactions containing 10 U
of RsaI at 37 °C for the C282Y mutation and MboІ for the
H63D mutation for 3 h. The products were resolved on 8%
polyacrylamide gel.
The statistical analyses were computed with SPSS
(Version 16). Data were expressed as means and standard
deviation (SD). All variables were tested by either oneway ANOVA or Student’s t-test. Categorical variables
were compared using the chi-square test. Variables with a
significant difference between the cardiovascular disease
(CVD) and non-CVD groups were evaluated by multiple
logistic regressions with forward stepwise analysis to
identify independent risk factors for CVD. Odds ratios
with 95% confidence intervals (95% CIs) were calculated
as an estimate of relative risk of CAD. The genotype at the
C282Y and H63D sites of the HFE gene was divided as wild
type and heterozygous or homozygous mutation. P < 0.05
was assumed to be significant.
3. Results
The prevalence of HFE mutations, including C282Y and
H63D alterations in patients and controls, are shown in
Table 2.

3.1. H63D mutations in HFE gene
Genotypes of H63D mutations were determined by
incubating the PCR product with MboІ restriction
enzyme and resolving the obtained fragments on 8%
polyacrylamide gel. The genotype and allele frequencies
of H63D mutations are shown in Table 2. Two genotypes,
CC and CG, were detected, but no homozygotes for the
H63D mutation were found. The chi-square test showed
a significant difference between the allele frequencies
of H63D mutations among case groups and controls (P
< 0.05). The frequency of CC and CG genotypes among
the cases was 45% and 55%, respectively, and among the
control subjects it was 66.7% and 33.3%, respectively.
There was a significant difference in genotype distribution
between the two groups (P < 0.01). We further analyzed
the associations of the two genotypes with the physiologic
variables shown in Table 3.
As shown in Table 3, for this mutation, two genotypes,
CC and CG, were analyzed separately for each group.
Studying the fasting blood sugar (FBS) values in the control
group between the two genotypes showed that there was a
significant difference between the two genotypes of H63D
mutation (P < 0.01). The differences between the CC and
CG genotypes in the patients group with respect to FBS
were not significant (P > 0.05). Additionally, there was
no significant association between the H63D mutation
and plasma lipids levels (TC, TG, LDL-C, HDL-C). The
difference in cholesterol levels between the two genotypes
in the patient group was minimal (P = 0.39). Overall,
no significant difference was observed in lipid profile
parameters between the control and patient groups (P
> 0.05). The relationship between the two genotypes in
HbA1c, micro albuminuria, and Cr levels also showed no
significant differences between the 2 groups (P > 0.05).
3.2. C282Y mutation in HFE gene
The C282Y mutation genotyping was done by incubating
the PCR product with RsaI restriction enzyme resolving
the fragments on an 8% polyacrylamide gel.
The genotype and allele frequencies of C282Y mutation
are shown in Table 4. The two heterozygote genotypes
detected included GG and GA, but no homozygote for the
C282Y mutation (AA) was found.

Table 2. Genotypic association of the H63D polymorphism with CAD.

Variable
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Genotype (%)
CC

CG

CAD subjects

45%

55%

Control subjects

66.7%

33.3%

OR (95% CI)

P-value

1.17 5.09 (2.42)

0.01
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Table 3. Analysis of physiologic variables in the control and case groups.
CAD subjects

Variable
N

Control subjects

CG

CC

P-value

CG

CC

P-value

70

75

-

54

91

-

BMI (kg/m )

29 ± 4.4

29.5 ± 4.6

0.46

24.62 ± 4

24.58 ± 3.1

0.89

FBS (mg/dL)

178.1 ± 20.1

190.4 ± 2.3

0.17

186.2 ± 80.4

190.1 ± 20.9

0.01

Cr. (mg/dL)

0.9 ± 0.2

1 ± 0.4

0.18

1 ± 0.4

1.1 ± 0.3

0.38

TG (mg/dL)

107.9 ± 2.0

105 ± 2.0

0.95

77.3 ± 1.5

72.7 ± 1.4

0.7

Total cholesterol (mg/dL)

196.4 ± 31.8

187 ± 20.7

0.39

201.5 ± 10.6

198.10 ± 10.7

0.49

HDL-C (mg/dL)

51.8 ± 11.9

49.7 ± 11.9

0.28

41.5 ± 11.9

38.6 ± 10.3

0.13

LDL-C (mg/dL)

91.1 ± 33.4

87.5 ± 34.8

0.53

52.2 ± 14.1

50.9 ± 11.6

0.56

HbA1c (mg/dL)

8.3 ± 1.9

8.6 ± 2.0

0.39

7.9 ± 1.6

7.7 ± 1.5

0.67

Microalbumin (mg/dL)

21.1 ± 6.9

20.2 ± 6.8

0.47

6.7 ± 2.1

6.4 ± 2.0

0.41

2

All data are expressed as a means (± SD), CAD: coronary artery disease; BMI: body mass index; FBS: fasting blood sugar, Cr: Creatine;
TG: Triglycerides; HDL-C: high-density lipoprotein–cholesterol; LDL-C: low-density lipoprotein–cholesterol.
Table 4. Genotypic associations of C282Y polymorphism with CAD.

Variable

Genotype (%)
GG

GA

CAD subjects

35%

65%

Control subjects

53.3%

46.7%

The frequency of GG and GA genotypes in the case group
was 35% and 65%, respectively, while in the control group
it was 46.7% and 53.3%, respectively. Statistical analysis by
the chi-square test showed a significant difference between
the allele frequencies of C282Y mutation among cases
and controls (P < 0.05). There was a significant difference
in genotype distribution among two groups (P < 0.01),
suggesting there was a significant relationship between this
genotype distribution and CAD status. In estimating risk
of CAD in the presence of the GA genotype, as compared
with the GG genotype, the heterozygote GA genotype was
associated with a significantly higher risk of CAD (P <
0.01) (adjusted odds ratio (OR) = 2. 12, 95% confidence
interval (CI) = 1.03–4. 34).
Investigation of the associations between the two
genotypes and physiologic variables are shown in Table 5.
Similar to the results obtained from statistical analysis
of H63D mutation, differences between the GA and
GG genotypes in the C282Y mutation in patient and
control groups were not significant. In addition, the
relationship between the two genotypes in terms of FBS,
lipid profile (TC, TG, LDL-C, HDL-C), BMI, HbA1c,

OR (95% CI)

P-value

1.03 4.34 (2.12)

0.03

micro albuminuria, and Cr levels showed no significant
differences in the control and patient groups. It could
be concluded that there is no relationship between these
physiologic variables and the C282Y mutation status in
both groups.
The results of stepwise multiple logistic regression
showed that the independent risk factors for CVD were
BMI, FBS, HDL, and total cholesterol level, and the
patients had all these risk factors (Table 6).
4. Discussion
To our knowledge, this is the first study on the evaluation
of whether mutations in the HFE gene might be
associated with increased risk of CAD in T2D patients
in Iranian population. Our result revealed a significant
difference between the allele frequencies of H63D and
C282Y mutations. This genotype distribution suggests
a significant association between HFE mutations and
CAD status. The C282Y heterozygote and homozygote
frequencies were higher in this study than in other
reported study. In addition, our results indicate that HFE
mutations are genetic markers for CAD risk in the Iranian
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Table 5. Analysis of physiologic variables in the control and case groups.
Variable

CAD subjects

Control subjects

GA

GG

P-value

GA

GG

P-value

86

59

-

70

75

-

BMI (kg/m )

29.3 ± 4.1

29.2 ± 5.1

0.97

24.6 ± 3.3

24.4 ± 3.7

0.71

FBS (mg/dL)

183.1 ± 20.2

187.7 ± 20.3

0.36

189.4 ± 90.3

187.9 ± 8.9

0.33

Cr. (mg/dL)

0.9 ± 0.3

1 ± 0.3

0.16

1.1 ± 0.4

1 ± 0.3

0.42

TG (mg/dL)

107.1 ± 2.0

105.3 ± 2.0

0.76

76.2 ± 1.4

72.3 ± 1.5

0.29

Total cholesterol (mg/dL)

197.4 ± 20.8

194.5 ± 20.8

0.42

175.6 ± 20.7

177.4 ± 20.6

0.19

HDL-C (mg/dL)

50.8 ± 12.1

50.6 ± 11.7

0.94

38.9 ± 11.2

40.4 ± 10.8

0.41

LDL-C (mg/dL)

88.4 ± 34.4

90.4 ± 33.8

0.72

50.5 ± 13.2

52.3 ± 12.3

0.39

HbA1c (%)

8.48 ± 2.0

8.46 ± 2.0

0.95

7.8 ± 1.6

7.8 ± 1.5

0.84

Microalbumin (mg/dL)

20.5 ± 6.3

20.8 ± 7.6

0.80

6.4 ± 2.0

6.6 ± 2.0

0.44

N
2

All data are expressed as a means (± SD), CAD: coronary artery disease; BMI: body mass index; FBS: fasting blood sugar, Cr: Creatine;
TG: Triglycerides; HDL-C: high-density lipoprotein–cholesterol; LDL-C: low-density lipoprotein–cholesterol.

population. The incidence of diabetes is globally increasing
and considered as an epidemic. It shows the importance
of investigations in this study due to macrovascular
complications that individuals with this condition may
experience and consequently CVDs. On the other hand,
CVDs are the most prevalent causes of mortality and
morbidity among people with diabetes (18).
Diabetic patients aggregate other comorbidities such
as obesity, dyslipidemia, and hypertension, which also
contribute to an increased risk for CVDs. It has been stated
that diabetes acts as an independent risk factor for CVD
in both men and women (19). Several forms of CVDs
are listed as the cause of death in 65% of patients with
Table 6. Stepwise multiple logistic regression analysis of factors
associated with CVD in patients with T2D (n = 145).
Risk factors a

OR (95% CI)

P-value b

BMI (kg/m2)

1.12 (1.21–1.04 )

0.036

FBS (mg/dL)

0.90 (0.98–0.83)

0.023

Total cholesterol

2.78 (1.04–4.52)

0.036

HDL-C (mg/dL)

1.43 (1.02–1.78)

0.002

a
Included factors: body mass index (BMI), fasting blood sugar
(FBS), total cholesterol, high-density lipoproteins (HDL), lowdensity lipoproteins (LDL), triglycerides (TG), HbA1c, creatine
(Cr), and microalbumin. OR: ratio; CI: odds confidence interval.
b
Based on Wald c2 statistic.
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diabetes. It could be expected that the frequency of HFE
gene mutations could be elevated among T2D patients and
as a result, among CAD cases (19,20). The HFE protein is a
type I transmembrane protein bound to β2-microglobulin,
and the mutated HFE protein at position 63 or position 282
can result in the lack of association with β2-microglobulin,
thereby disrupting the association of HFE with transferrin
receptor, which leads to increased iron absorption (7).
The identification of HFE variants (C282Y and
H63D) provides the unique opportunity to test whether
genetic polymorphisms that are associated with tissue
iron accumulation may also be considered as CAD risk
factors (18). Some types of HFE genotypes (C282Y/
H63D or heterozygous C282Y carriers) are associated
with increased risk of different disorders like hereditary
hemochromatosis and diabetes (10). Our paper shows that
the differences between the CC and CG genotypes in the
patient group in regards to FBS were not significant (P >
0.05) because PGC-1α participates in lipid metabolism
and the plasma lipid levels were stratified according to
these two SNP variants.
The association of HFE gene mutations and the risk of
T2D has been extensively studied in different populations
(9,21,22). However, the results of these investigations
were inconsistent (7). For example, in a study by Surber
et al. (23), the C282Y mutation was not associated
with an increased risk of CAD or severity of coronary
lesions. This study did not find a linkage between the
C282Y mutation and previous myocardial infarction
or depressed left ventricular ejection fraction (23). In
an angiographically controlled population, ferritin and
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transferrin concentrations were not associated with CAD
(24). In a population (265 patients) with proven premature
CAD a lower frequency of the C282Y mutation, compared
with healthy controls, was found (25). Therefore, this
result leads us to longitudinal studies with large samples
of these mutations to study its association with CAD in
diabetic patients.
To obtain an estimate of the prevalence of the C282Y
and H63D mutations in the Iranian population, we
conducted a nested cross-sectional study of 145 incident
cases of CAD with a history of T2D and 145 matching
control subjects. We then examined the prevalence of the
2 mutations in case and control subjects. A significant
difference between the allele frequencies of H63D
and C282Y mutations among cases and controls was
observed. This genotype distribution suggests a significant
association between HFE mutations and CAD status.
Study on Italian (26), United States, and United Kingdom
(9) populations indicated the possible contribution of HFE
mutations to iron status disorders, and consequently to
CAD risk. In a subset of patients, indexes of physiologic
variables including FBS, total cholesterol, HDL, LDL, TG,
BMI, HbA1c, and grand microalbumin was not associated
with cardiovascular end points. It could be concluded that
there is no relationship between these physiologic variables

and HFE gene status or CAD as a diabetic complication.
The reason for the lack of this association could be related
to the small sample size in our study. The results showed
that the prevalence of CVD and insufficient control of
CVD risk factors among our patients were high. These
findings are in agreement with other studies in different
regions (27,28). More aggressive interventions are crucial
for patients with diabetes mellitus, including better patient
education and more aggressive control of glycaemia,
hypertension, hyperlipidemia, and metabolic syndrome.
In conclusion, our findings provide evidence of an
association between C282Y and H63D mutations and the
development of CAD in diabetic patients, thus indicating
that HFE mutations are genetic markers of CAD risk in
Iranian population. Similar conclusions were reached
by Carolina Pardo Silva et al. (12), in a study in which
they reported significant association between HFE gene
mutations and increased risk of CAD in women but not
in men.
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